Noticias de GH_US
Noticias del mercado
Últimas noticias sobre GH_US — 417 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
Guardant Health, Inc. (NASDAQ:GH) faces a costly legal setback after a US court ordered the cancer-testing company to pay more than $245.2 million in a DNA-sequencing patent dispute. The final judgment upheld a 2023 jury verdict finding that Guardant willfully infringed two DNA-sequencing patents asserted by TwinStrand Biosciences and the University of Washington. The financial […]
FDA cleared Guardant Health’s Guardant360 CDx as a companion diagnostic for AstraZeneca’s ETCAMAH (camizestrant) in advanced breast cancer. T | Bitget crypto news!
Price-action only: Guardant Health Inc. (GH) movements set the tone for institutional models. Behavioral Patterns of GH and Institutional Flows
El analista de B of A Securities, Michael Ryskin, mantuvo una calificación de Compra en Guardant Health (NASDAQ: GH) y elevó el precio objetivo de 135 dólares a 190 dólares, enfatizando la confianza en la empresa.
Get the latest Guardant Health Inc (NASDAQ: GH) share price and stock news at Kalkine. Access the latest movements, expert commentary, and general investing advice on the Guardant Health Inc (NASDAQ:GH) at Kalkine.
A Delaware federal judge has refused to throw out litigation accusing Tempus AI Inc. of infringing Guardant Health Inc. patents covering technology used to analyze cancer-related genetic data and help guide testing and treatment.
Guardant Suits Against Tempus AI Clear Dismissal Bids
Página 9 de 21